Clinical Trial Update: Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing LY2181308 in combination with docetaxel versus docetaxel alone for non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• LY2181308

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-05-24